FDA Approves First New Class of Non-Opioid Pain Drug, Offering Hope for Millions Suffering from Acute Pain

FDA Approves First Non-Opioid Pain Reliever: Journavx by Vertex Pharmaceuticals

The FDA approved Vertex Pharmaceuticals's Journavx (suzetrigine) in January 2025, marking the first non-opioid pain reliever.

FDA Approves Noroxone Nasal Spray That Reverses Narcan's Effects

The FDA has approved a new nasal spray called noroxone that reverses the effects of Narcan, with the stated goal of increasing fatalities am

FDA Approves Another Over-the-Counter Naloxone Nasal Spray for Opioid Overdose Reversal

The FDA has approved another over-the-counter naloxone nasal spray (Rextovy, 4-mg) for emergency opioid overdose reversal, joining other non

Trump administration orders federally funded health programs to shift away from overdose prevention and harm reduction

The Trump administration has ordered federally funded health programs to adopt new priorities within days, including emphasizing "parental a

FDA Announces Plans to Restrict Non-Approved GLP-1 Drugs in Compounded Medications

The FDA is announcing its intent to take action against non-FDA-approved GLP-1 drugs, specifically targeting GLP-1 active pharmaceutical ing

Morning Consult study: Here are US consumers’ most trusted brands in 2026